Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Novartis AG

Market Cap 273B 238B 220B 206B 386B 25,767B 389B 2,619B 1,019B 12,668B 1,024B 1,002B 44,010B P/E 2026 *
20.3x
P/E 2027 * 17.4x
Enterprise Value 305B 266B 246B 230B 432B 28,815B 435B 2,929B 1,140B 14,167B 1,145B 1,120B 49,217B EV / Sales 2026 *
5.35x
EV / Sales 2027 * 4.98x
Free-Float
91.66%
Yield 2026 *
3.05%
Yield 2027 * 3.14%
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 68 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 268B
+0.67%-2.06%+43.53%+141.68% 980B
+1.04%-2.02%+52.58%+39.41% 550B
+6.23%+3.70%+25.04%+67.22% 382B
-0.06%-3.09%+23.33%+16.78% 316B
+0.42%+0.68%+27.54%+14.57% 272B
+2.39%+5.02%-33.44%-44.76% 199B
+1.98%-2.04%+26.04%+49.52% 182B
+1.01%+0.22%+17.31%+59.48% 154B
-0.58%-3.65%+4.25%-35.32% 144B
Average +1.35%-2.76%+20.69%+34.29% 353.09B
Weighted average by Cap. +1.39%-3.55%+30.63%+62.81%

Financials

2026 *2027 *
Net sales 57.02B 49.82B 46.08B 43.01B 80.75B 5,388B 81.34B 548B 213B 2,649B 214B 209B 9,203B 60.42B 52.8B 48.84B 45.58B 85.58B 5,710B 86.2B 580B 226B 2,807B 227B 222B 9,753B
Net income 14.15B 12.36B 11.44B 10.67B 20.04B 1,337B 20.18B 136B 52.87B 657B 53.12B 51.97B 2,284B 15.67B 13.69B 12.67B 11.82B 22.2B 1,481B 22.36B 151B 58.57B 728B 58.84B 57.57B 2,530B
Net Debt 32.26B 28.19B 26.07B 24.34B 45.69B 3,049B 46.02B 310B 121B 1,499B 121B 118B 5,207B 28.3B 24.73B 22.87B 21.35B 40.08B 2,674B 40.37B 272B 106B 1,315B 106B 104B 4,568B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
146.50USD
Average target price
154.88USD
Spread / Average Target
+5.72%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!